# A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia

> **NCT05952037** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **BeOne Medicines** · enrollment: 114 (actual)

## Conditions studied

- Waldenstrom Macroglobulinemia
- Waldenstrom's Macroglobulinemia Recurrent
- Waldenstrom's Macroglobulinemia Refractory

## Interventions

- **DRUG:** Sonrotoclax
- **DRUG:** Zanubrutinib

## Key facts

- **NCT ID:** NCT05952037
- **Lead sponsor:** BeOne Medicines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-10-23
- **Primary completion:** 2026-09-22
- **Final completion:** 2028-08
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2026-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05952037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05952037, "A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05952037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*